UNC Lineberger Comprehensive Cancer Center
LCCC 2534-ATL is an early-stage (Phase 1), single-center clinical study evaluating the safety of CAR T-cell therapy in children and adults with high-grade gliomas (HGGs), which are aggressive brain cancers. The treatment, called iC9-CAR.B7-H3 T cells, uses modified immune cells designed to recognize and attack cancer cells with a protein called B7-H3. The treatment also includes a safety switch (iC9) designed to help stop the modified cells if serious side effects occur. Earlier studies of B7-H3-targeted CAR T-cell therapy have shown encouraging safety results, with some patients experiencing tumor shrinkage. This study will further evaluate the safety and tolerability of the treatment in children and adults with high-grade gliomas type brain tumors. The study will use a 3+3 dose-escalation design to evaluate increasing doses and identify the safest appropriate dose. The results will help determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), which is the dose selected for further study. Participants who qualify will have blood collected to produce the modified T cells. Three treatment doses will be administered two weeks apart. Additional doses may be given. Participants will be monitored for 15 years after treatment ends or is discontinued to assess potential long-term side effects related to genetic modification of the cells.
Inclusion Criteria * Provide written informed consent/assent and HIPAA authorization, signed by the subject, parent/guardian, or legally authorized representative, after the study information has been explained and understood. * Meet the age requirements at consent/assent: * Adult cohort: ≥18 years. * Pediatric cohort: ≥2 and \<18 years, with a minimum body weight of 10 kg at enrollment. * Karnofsky performance status ≥50 (\>16 years) or Lansky performance status ≥50 (≤16 years). Participants unable to walk because of paralysis but able to sit upright in a wheelchair will be considered a…
Participants receive increasing doses of genetically modified immune cells (iC9-CAR.B7-H3 T cells) to evaluate safety and determine the recommended dose for future studies.